한글목차

신경질환 치료제 세계 시장은 2030년까지 1,497억 달러에 달할 전망

2023년에 1,164억 달러로 추정되는 신경질환 치료제 세계 시장은 2030년에는 1,497억 달러에 이르고, 분석 기간 2023-2030년 CAGR은 3.7%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 항콜린제 클래스는 CAGR 4.0%로 성장을 지속하고, 분석 기간 종료 시에는 452억 달러에 달할 것으로 예측됩니다. 진통제 등급별 부문의 성장률은 분석 기간 동안 CAGR 4.4%로 추정됩니다.

미국 시장은 317억 달러로 추정, 중국은 CAGR 7.0%로 성장 예측

미국의 신경질환 치료제 시장은 2023년 317억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 313억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 7.0%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.2%와 2.8%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 2.0%로 성장할 것으로 예측됩니다.

세계의 신경 질환 치료제 시장 - 주요 촉진요인과 동향 요약

신경 질환에는 뇌, 척수, 말초 신경을 포함한 신경계에 영향을 미치는 광범위한 질병이 포함됩니다. 이러한 질병은 쇠약해질 수 있으며, 알츠하이머병, 파킨슨병, 다발성 경화증, 간질, 뇌졸중 등의 질환을 포함합니다. 신경 질환에 대한 치료 접근법은 특정 질병에 따라 크게 다르지만 일반적으로 증상을 관리하고 질병의 진행을 늦추고 환자의 삶의 질을 향상시키는 것을 목표로합니다. 치료에는 약물 요법, 물리 요법, 작업 요법, 생활 습관 개선, 경우에 따라 외과 적 개입이 포함됩니다.

신경 질환의 치료 분야는 지난 수십년동안 큰 발전을 이루었습니다. 질병 개질 요법의 개발은 다발성 경화증과 파킨슨 병과 같은 질병의 관리를 변화시키고 환자에게 대증 요법에 머무르지 않는 옵션을 제공했습니다. 예를 들어, 단클론항체 및 기타 생물학적 제제의 도입은 이러한 질환의 근본적인 병태생리학을 표적으로 하는 새로운 길을 제공하였습니다. 또한 신경 영상과 바이오마커 연구의 진보로 조기 진단과 맞춤 치료 계획이 강화되고 있습니다. 또한, 척수강 펌프 및 경피 패치와 같은 혁신적인 약물 전달 시스템은 신경학적 약물 투여의 효능 및 편리성을 향상시킵니다.

신경 질환 치료제 시장의 성장은 여러 요인에 의해 견인되고 있습니다. 첫째, 특히 고령화 사회에서 신경 질환의 유병률이 증가함에 따라 효과적인 치료에 대한 수요가 증가하고 있습니다. 둘째, 생명공학과 제약 연구의 진보로 유전자 치료와 신경보호제 등 새롭게 개선된 치료법이 차례로 개발되고 있습니다. 신흥 시장에서 건강 관리 인프라의 확장은 신경학적 치료에 대한 접근을 향상시키고 시장 성장에 기여합니다. 또한 제약회사, 학술기관, 연구기관의 전략적 제휴로 혁신적인 치료법의 발견과 상업화가 가속화되고 있습니다. 원격 의료 및 웨어러블 단말기를 포함한 디지털 건강 기술의 상승은 환자의 모니터링과 관리를 강화하고 결과를 개선합니다. 마지막으로, 신경학 연구에 대한 자금 증가와 종합적인 치료 지침의 개발은 신경 질환 관리에 대한 보다 체계적이고 효과적인 접근을 촉진하고 있습니다.

조사 대상 기업 예(전 86건)

• AstraZeneca PLC
• Biogen, Inc.
• Biohaven, Ltd.
• Eisai Co., Ltd.
• H. Lundbeck A/S
• Ionis Pharmaceuticals, Inc.
• Mitsubishi Tanabe Pharma Corporation
• Neurelis, Inc.
• Neurocrine Biosciences, Inc.
• Neurona Therapeutics, Inc.
• Ovid Therapeutics, Inc.
• Pfizer, Inc.
• Sanofi SA
• UCB SA
• Voyager Therapeutics, Inc.

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트(UAE)
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Neurologic Disorders Therapeutics Market to Reach US$149.7 Billion by 2030

The global market for Neurologic Disorders Therapeutics estimated at US$116.4 Billion in the year 2023, is expected to reach US$149.7 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2023-2030. Anticholinergic Drug Class, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$45.2 Billion by the end of the analysis period. Growth in the Analgesics Drug Class segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$31.7 Billion While China is Forecast to Grow at 7.0% CAGR

The Neurologic Disorders Therapeutics market in the U.S. is estimated at US$31.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$31.3 Billion by the year 2030 trailing a CAGR of 7.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Neurologic Disorders Therapeutics Market - Key Drivers and Trends Summarized

Neurologic disorders encompass a broad range of conditions that affect the nervous system, including the brain, spinal cord, and peripheral nerves. These disorders can be debilitating and include diseases such as Alzheimer's, Parkinson's, multiple sclerosis, epilepsy, and stroke, among others. The therapeutic approaches for neurologic disorders vary widely depending on the specific condition, but generally aim to manage symptoms, slow disease progression, and improve the quality of life for patients. Treatments can include medications, physical and occupational therapy, lifestyle changes, and, in some cases, surgical interventions.

The field of neurologic disorder therapeutics has seen significant advancements over the past few decades. The development of disease-modifying therapies has transformed the management of conditions like multiple sclerosis and Parkinson's disease, offering patients options that go beyond symptomatic relief. For instance, the introduction of monoclonal antibodies and other biologic drugs has provided new avenues for targeting the underlying pathophysiology of these diseases. Advances in neuroimaging and biomarker research have also enhanced early diagnosis and personalized treatment plans. Moreover, innovative drug delivery systems, such as intrathecal pumps and transdermal patches, have improved the efficacy and convenience of administering neurologic medications.

The growth in the neurologic disorders therapeutics market is driven by several factors. Firstly, the increasing prevalence of neurologic conditions, particularly among aging populations, has heightened the demand for effective treatments. Secondly, advancements in biotechnology and pharmaceutical research are continuously leading to the development of new and improved therapies, including gene therapies and neuroprotective agents. The expansion of healthcare infrastructure in emerging markets has also facilitated better access to neurologic care, contributing to market growth. Additionally, strategic collaborations between pharmaceutical companies, academic institutions, and research organizations are accelerating the discovery and commercialization of innovative treatments. The rise of digital health technologies, including telemedicine and wearable devices, is enhancing patient monitoring and management, leading to better outcomes. Lastly, increased funding for neurologic research and the development of comprehensive treatment guidelines are fostering a more structured and effective approach to managing neurologic disorders.

Select Competitors (Total 86 Featured) -

• AstraZeneca PLC
• Biogen, Inc.
• Biohaven, Ltd.
• Eisai Co., Ltd.
• H. Lundbeck A/S
• Ionis Pharmaceuticals, Inc.
• Mitsubishi Tanabe Pharma Corporation
• Neurelis, Inc.
• Neurocrine Biosciences, Inc.
• Neurona Therapeutics, Inc.
• Ovid Therapeutics, Inc.
• Pfizer, Inc.
• Sanofi SA
• UCB SA
• Voyager Therapeutics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Neurologic Disorders Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Neurologic Disorders Drives Demand for Therapeutics
  • Advancements in Neurotherapeutics Propel Market Growth
  • Growing Awareness of Neurologic Health Expands Addressable Market Opportunity
  • Development of Precision Medicine and Targeted Therapies Strengthens Business Case
  • Innovations in Neurostimulation and Neuromodulation Therapies Generate Market Interest
  • Development of Regenerative Medicine and Stem Cell Therapies Propels Market Growth
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Neurologic Disorders Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Neurologic Disorders Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Anticholinergic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Anticholinergic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Anticholinergic Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Analgesics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Analgesics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Analgesics Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Antiepileptic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Antiepileptic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Antiepileptic Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• JAPAN
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• CHINA
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• EUROPE
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Neurologic Disorders Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• FRANCE
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• GERMANY
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• INDIA
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 116: India Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: India 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 119: India Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: India 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Neurologic Disorders Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Neurologic Disorders Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• AFRICA
  • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION